IKDCs or B220+ NK cells are pre-mNK cells

Zitvogel, Laurence; Housseau, Franck

doi:10.1182/blood-2012-03-415026

Cited by 10 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…“Interferon-producing killer dendritic cells” have been redefined as NK-cell precursors and, consequently, they have been renamed pre-mNK cells (30, 31). A potentially equivalent cell type has also been identified in humans and, in both mice and humans, pre-mNK cells display a potent anti-tumoral potential (22, 32, 56, 59).…”

Section: Key Outstanding Questionsmentioning

confidence: 99%

“…However, the study of IKDC for their anti-tumoral properties was rapidly halted as a debate emerged regarding both the cellular lineage origin of IKDC and their hybrid cellular properties (5, 25–29). IKDC have now been recognized as part of the NK-cell lineage (26–28, 30) and have since been renamed pre-mature NK (mNK) cells (30, 31). As the debate on the lineage origin comes to a close, the means by which pre-mNK cells carry out the elimination of tumors needs to be revisited.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells

Guimont-Desrochers

Lesage

2013

Front. Immunol.

View full text Add to dashboard Cite

Interferon-producing killer dendritic cells (IKDC) were first described for their outstanding anti-tumoral properties. The “IKDC” terminology implied the description of a novel DC subset and initiated a debate on their cellular lineage origin. This debate shifted the focus away from their notable anti-tumoral potential. IKDC were recently redefined as precursors to mature NK (mNK) cells and consequently renamed pre-mNK cells. Importantly, a putative human equivalent of pre-mNK cells was recently associated with improved disease outcome in cancer patients. It is thus timely to revisit the functional attributes as well as the therapeutic potential of pre-mNK cells in line with their newly defined NK-cell precursor function.

show abstract

Section: Key Outstanding Questionsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells

Guimont-Desrochers

Lesage

2013

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In humans, IL18 promotes development and expansion of CD56 high CD11c þ CD25 high CD86 high HLA-DR high HLA-DQ high NK cells (termed helper NK cells) in the presence of IL2, which in turn enhance the expansion of effector gd T cells (25)(26)(27). It is most likely that human helper NK cells are a counterpart of mouse pre-mNK cells (28,29). If this is the case, mouse pre-mNK cells may induce the development and expansion of effector T cells.…”

Section: Discussionmentioning

confidence: 99%

“…3B, Table 1). The B220 þ NK cells also expressed CD11b, CD11c, and CD122 and were most likely to be pre-mNK cells (Table 2), formerly called IFNg-producing killer dendritic cells (28,29).…”

Section: B220mentioning

confidence: 99%

“…In humans, IL18 promotes the expansion of CD56 bright CD11c þ HLA-DR þ helper NK cells, which may be a human counterpart of mouse precursors of mature natural killer (pre-mNK) cells, previously referred to as IFN-producing killer dendritic cells (28,29). IL18-induced NKlineage cells exhibit potent antitumor activity, although NK cells expressing inhibitory receptors, such as CTLA-4 and PD-1, may have regulatory functions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Yoshiya

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Recent clinical trials and animal models demonstrated that immune checkpoint blockade enhanced effector cell responses and tumor rejection; however, further development and improvement of cancer immunotherapy is necessary for more favorable objective responses. In this study, we examined the effect of IL18 on the antitumor effect of immune checkpoint inhibitors.Experimental Design: We examined the effect of IL18 on the peritoneal dissemination of CT-26 cells or tail vein injection metastasis of B16/F10 cells using antiprogrammed death-1 ligand-1 (aPD-L1) and/or anti-CTL-associated antigen-4 (aCTLA-4) mAbs.Result: Massive ascites developed after intraperitoneal inoculation of CT-26, resulting in animal death within 30 days. Treatment of mice with aPD-L1 and/or aCTLA-4 significantly prolonged their survival, and a combination of the antibodies and IL18 provided a much greater therapeutic benefit. The combination modality led to the accumulation of precursor of mature natural killer (pre-mNK) cells in the peritoneal cavity together with increased CD8 þ T and decreased CD4Depletion of the pre-mNK cells abrogated the therapeutic effects and increased the number ofThe combination treatment also suppressed tail vein injection metastasis of B16/F10 cells. Conclusions:The results demonstrated that IL18 enhanced therapeutic effects of immune checkpoint blockade against peritoneal dissemination of carcinoma or tail vein injection metastasis of melanoma through accumulation of pre-mNK cells, memorytype CD8 þ T cells, and suppression of CD4

show abstract